• Publications
  • Influence
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison
The metabolic syndrome is highly prevalent in US schizophrenia patients and represents an enormous source of cardiovascular risk, especially for women, so clinical attention must be given to monitoring for this syndrome, and minimizing metabolic risks associated with antipsychotic treatment. Expand
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
The hypotheses that patients treated with clozapine experience significant weight gain and lipid abnormalities and appear to be at increased risk for developing diabetes mellitus are supported. Expand
Regionally localized thinning of the cerebral cortex in schizophrenia
Patients with chronic schizophrenia showed widespread cortical thinning that particularly affected the prefrontal and temporal cortices, which might reflect underlying neuropathological abnormalities in cortical structure. Expand
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
The data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia. Expand
Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance
Aberrant WM performance and brain activation in schizophrenia may reflect dysfunction of frontostriatal circuitry that subserves WM, and the contribution of the anatomical components of this circuitry to WM deficits is elucidated. Expand
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
  • D. Goff, J. Coyle
  • Psychology, Medicine
  • The American journal of psychiatry
  • 1 September 2001
Dysfunction of glutamatergic neurotransmission may play an important role in the pathophysiology of schizophrenia, especially of the negative symptoms and cognitive impairments associated with the disorder, and is a promising target for drug development. Expand
Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
Poor attention and impaired memory are enduring and core features of schizophrenia. These impairments have been attributed either to global cortical dysfunction or to perturbations of specificExpand
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
These results are consistent with recent evidence of increased cardiac mortality in schizophrenia patients and the impact of cigarette smoking is clear, while the relative contributions to cardiac risk of specific antipsychotic agents, diet, exercise, and quality of medical care remain to be clarified. Expand
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
The suggested guidelines represent reasonable starting points for trial design of cognitive-enhancing drugs, with the understanding that new data, subsequent findings, or other methodological considerations may lead to future modifications. Expand
Reduced Sleep Spindles and Spindle Coherence in Schizophrenia: Mechanisms of Impaired Memory Consolidation?
It is suggested that abnormal spindle generation impairs sleep-dependent memory consolidation in schizophrenia, contributes to positive symptoms, and is a promising novel target for the treatment of cognitive deficits in schizophrenia. Expand